Poseida Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Kristin Yarema
Chief executive officer
US$2.6m
Total compensation
CEO salary percentage | 14.7% |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | 2.3yrs |
Board average tenure | 3yrs |
Recent management updates
Recent updates
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$109m |
Dec 31 2023 | US$3m | US$381k | -US$123m |
Compensation vs Market: Kristin's total compensation ($USD2.58M) is about average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Insufficient data to compare Kristin's compensation with company performance.
CEO
Kristin Yarema (52 yo)
less than a year
Tenure
US$2,581,106
Compensation
Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board | 6.3yrs | US$3.82m | 0.15% $ 459.8k | |
President | less than a year | US$2.58m | no data | |
Chief Financial Officer | 3.8yrs | no data | 0.073% $ 224.2k | |
Chief Operations Officer | 2.3yrs | no data | no data | |
Chief People & Administration Officer | 5.3yrs | no data | no data | |
Senior VP of Investor Relations & Corporate Communications | less than a year | no data | no data | |
General Counsel | 3.8yrs | US$978.34k | 0.041% $ 124.2k | |
Chief Scientific Officer of Cell Therapy | 4.3yrs | no data | no data | |
Senior Vice President of Regulatory Affairs | 2.6yrs | no data | no data | |
Senior VP & Chief Patent Counsel | 2.3yrs | no data | no data | |
Senior Vice President of Business Development | 2.3yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: PSTX's management team is considered experienced (2.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board | 6.3yrs | US$3.82m | 0.15% $ 459.8k | |
President | less than a year | US$2.58m | no data | |
Lead Independent Director | 5.8yrs | US$175.11k | 0.020% $ 62.1k | |
Chairman of Cell Therapy Scientific Advisory Board | 3.2yrs | no data | no data | |
Chairman of Gene Therapy Scientific Advisory Board | 1.8yrs | no data | no data | |
Independent Director | 5.3yrs | US$149.11k | 0.031% $ 93.7k | |
Independent Director | 2.8yrs | US$155.28k | 0.020% $ 62.1k | |
Independent Director | 2yrs | US$150.28k | 0.014% $ 41.4k | |
Independent Director | 3.4yrs | US$140.11k | 0.020% $ 62.1k | |
Member of Scientific Advisory Board | 3yrs | no data | no data | |
Member of Scientific Advisory Board | 3yrs | no data | no data | |
Member of Scientific Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
65yo
Average Age
Experienced Board: PSTX's board of directors are considered experienced (3 years average tenure).